SlideShare a Scribd company logo
WHEN DO DRUG
PATENTS EXPIRE?
DrugPatentWatch.com
info@DrugPatentWatch.com
DrugPatentWatch.comDrugPatentWatch.com
Contents
• Slide 3: Patents and Drug Development
• Slide 4: Patent Claim Types
• Slide 8: Patent Extension
• Slide 9: Non-Patent Protection
• Slide 12: Patent and Regulatory Exclusivity Timeline
• Slide 15: Summary: When can Generics Launch?
DrugPatentWatch.comDrugPatentWatch.com
Types of Patent Claims
The ‘claims’ define what a patent protects
Product patents
• Cover the active ingredient or compound in a drug
Process patents
• Cover a process for manufacturing a drug
Method-of-use patents
• Protect a particular method of using a drug (e.g. specific diseases)
Formulation patents
• Cover active and inactive ingredients in a drug (e.g. final dosage form, tablet, or
capsule)
DrugPatentWatch.comDrugPatentWatch.com
Patent Claims and Generic Entry
Product claims
• Generally impossible to work around. Patents containing these claims must all
expire or be invalidated
Process claims
• It may be possible to develop alternative production methods
Method-of-use claims
• A generic may gain approval for unpatented uses, and hope that physicians will
prescribe the drug off-label for the patented uses
Formulation claims
• Generics may be able to work around some formulation patents
DrugPatentWatch.comDrugPatentWatch.com
DrugPatentWatch Shows Patent Claim Types
DrugPatentWatch.comDrugPatentWatch.com
DrugPatentWatch Also Shows Patent Claims
DrugPatentWatch.comDrugPatentWatch.com
When do Drug Patents Expire
Short Answer:20 years from the date of filing
But it is much, much, more complicated…
DrugPatentWatch.comDrugPatentWatch.com
Patent Extensions and Regulatory Exclusivities
Enable recovery of time spent waiting for regulatory approval
US: Hatch-Waxman Patent Extensions
• Listed as patent expiration date by DrugPatentWatch
EU: Supplementary Protection Certificates
• Ex-US patent information shows estimated expiration date. SPC expiry listed
separately.
DrugPatentWatch.comDrugPatentWatch.com
Non-Patent Regulatory Exclusivities
New Chemical Entity: 5 years
• A compound never before approved for any indication
New Clinical Investigation: 3 years
• A new formulation, new patient population, new dosage regimen, etc.
Orphan Drug: 7 years
• Treatments for rare diseases
Conduct Pediatric Clinical Trials Following FDA Request: 6 months
First Successful Patent Challenge: 6 months generic exclusivity
DrugPatentWatch.comDrugPatentWatch.com
DrugPatentWatch has US Regulatory Exclusivity
and EU SPCs
DrugPatentWatch.comDrugPatentWatch.com
DrugPatentWatch Lists Exclusivity Expirations
DrugPatentWatch.comDrugPatentWatch.com
Drug Patents are Generally Filed Years Before Approval
Patent (20 years + extensions)
Drugapproved
Patentfiled
Patentexpiration
←Clinical testing→
DrugPatentWatch.comDrugPatentWatch.com
Most Regulatory Exclusivities Start From Drug Approval
5 years
Patent (20 years + extensions)
3 years New Clinical Investigation
New Chemical Entity
7 years Orphan Drug Exclusivity
Drugapproved
Patentfiled
Patentexpiration
←Clinical testing→
DrugPatentWatch.comDrugPatentWatch.com
Pediatric Exclusivity and SPCs (EU) Start When Patents Expire
5 years
Patent (20 years + extensions)
3 years New Clinical Investigation
New Chemical Entity
Pediatric Exclusivity / SPC
7 years Orphan Drug Exclusivity
Drugapproved
Patentfiled
Patentexpiration
Possiblegenericentry
←Clinical testing→
DrugPatentWatch.comDrugPatentWatch.com
Summary: When Can Generics Launch?
All ‘blocking’ patents must be expired (or invalidated)
• Composition of matter, core formulation, etc.
• Some method of use or enhanced formulation patents may
not fully block generics.
All regulatory exclusivities must be expired
• NCE, pediatric exclusivity, etc.

More Related Content

What's hot

MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
Swapnil Fernandes
 
Product life cycle management
Product life cycle managementProduct life cycle management
Product life cycle management
Vikas Rathee
 
Patent Issues and 180-Day Exclusivity
Patent Issues and 180-Day ExclusivityPatent Issues and 180-Day Exclusivity
Patent Issues and 180-Day Exclusivity
Michael Swit
 
NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)
Navalika Polishetty
 
Japan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval ProcessJapan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval Process
EMERGO
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
Office of Health Economics
 
Generic drug regulations for beginners.
Generic drug regulations for beginners.Generic drug regulations for beginners.
Generic drug regulations for beginners.
GMP EDUCATION : Not for Profit Organization
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpments
JITHIN K JOY
 
Pharmaceutical patent
Pharmaceutical patent Pharmaceutical patent
US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – Comparative
Girish Swami
 
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyFundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Hitendra Singh
 
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
Mohamed Fazil M
 
Marketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countriesMarketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countriesAkshay Saxena
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Aakashdeep Raval
 
Anda
AndaAnda
Medical Devices Regulation (MDR) 2017/745 - Clinical investigations
Medical Devices Regulation (MDR)  2017/745 - Clinical investigationsMedical Devices Regulation (MDR)  2017/745 - Clinical investigations
Medical Devices Regulation (MDR) 2017/745 - Clinical investigations
Arete-Zoe, LLC
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilGaurav Kr
 
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANMEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANDeveshDRA
 

What's hot (20)

MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
 
Product life cycle management
Product life cycle managementProduct life cycle management
Product life cycle management
 
Patent Issues and 180-Day Exclusivity
Patent Issues and 180-Day ExclusivityPatent Issues and 180-Day Exclusivity
Patent Issues and 180-Day Exclusivity
 
NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)
 
Japan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval ProcessJapan PMDA Medical Device Regulatory Approval Process
Japan PMDA Medical Device Regulatory Approval Process
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
 
Generic drug regulations for beginners.
Generic drug regulations for beginners.Generic drug regulations for beginners.
Generic drug regulations for beginners.
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpments
 
Pharmaceutical patent
Pharmaceutical patent Pharmaceutical patent
Pharmaceutical patent
 
US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – Comparative
 
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyFundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
 
Para i iv orange book
Para i iv orange bookPara i iv orange book
Para i iv orange book
 
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
 
Marketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countriesMarketing Authorization procedures in developed and developing countries
Marketing Authorization procedures in developed and developing countries
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
Post-NOC changes
Post-NOC changesPost-NOC changes
Post-NOC changes
 
Anda
AndaAnda
Anda
 
Medical Devices Regulation (MDR) 2017/745 - Clinical investigations
Medical Devices Regulation (MDR)  2017/745 - Clinical investigationsMedical Devices Regulation (MDR)  2017/745 - Clinical investigations
Medical Devices Regulation (MDR) 2017/745 - Clinical investigations
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazil
 
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPANMEDICAL DEVICE APPROVAL PROCESS IN JAPAN
MEDICAL DEVICE APPROVAL PROCESS IN JAPAN
 

Viewers also liked

Hatch Waxman Act
Hatch Waxman ActHatch Waxman Act
Hatch Waxman Act
Naveen Kumar
 
Evergreening of patents in pharma field (Rahul Pokale)
Evergreening of patents in pharma field (Rahul Pokale)Evergreening of patents in pharma field (Rahul Pokale)
Evergreening of patents in pharma field (Rahul Pokale)
rahul_pharma
 
Biopolymers_highlights2014-2015
Biopolymers_highlights2014-2015Biopolymers_highlights2014-2015
Biopolymers_highlights2014-2015Florian Graichen
 
Knowledge management
Knowledge managementKnowledge management
Knowledge management
Ruthvik Biradar
 
Produce the Perfect Product Launch
Produce the Perfect Product LaunchProduce the Perfect Product Launch
Produce the Perfect Product Launch
The Marx Group
 
Stanford DrupalCamp 2014 - A Perfect Launch, Every Time
Stanford DrupalCamp 2014 - A Perfect Launch, Every TimeStanford DrupalCamp 2014 - A Perfect Launch, Every Time
Stanford DrupalCamp 2014 - A Perfect Launch, Every Time
Suzanne Aldrich
 
Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...
Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...
Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...
Ioanna Michalopoulou
 
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
 
What you want to know about generic drugs
What you want to know about generic drugsWhat you want to know about generic drugs
What you want to know about generic drugs
stewart granger
 
Biosimilars 10-21-2010
Biosimilars 10-21-2010Biosimilars 10-21-2010
Biosimilars 10-21-2010
briandorn
 
Timeline of Biosimilars Pathways
Timeline of Biosimilars PathwaysTimeline of Biosimilars Pathways
Timeline of Biosimilars Pathways
Small World Social
 
Biosimilars Law in Flux
Biosimilars Law in FluxBiosimilars Law in Flux
Biosimilars Law in Flux
briandorn
 
U.S. Biosimilars - Red Flags for Patent Attorneys
U.S. Biosimilars - Red Flags for Patent AttorneysU.S. Biosimilars - Red Flags for Patent Attorneys
U.S. Biosimilars - Red Flags for Patent Attorneys
Knobbe Martens - Intellectual Property Law
 
Monoclonal Antibodies Dawn Of A New Era
Monoclonal Antibodies Dawn Of A New EraMonoclonal Antibodies Dawn Of A New Era
Monoclonal Antibodies Dawn Of A New Era
Wouter Pors
 
A history of pharma v1
A history of pharma v1A history of pharma v1
A history of pharma v1
Sheila Ash
 
New sources of big data for precision medicine: are we ready?
New sources of big data for precision medicine: are we ready?New sources of big data for precision medicine: are we ready?
New sources of big data for precision medicine: are we ready?
Health and Biomedical Informatics Centre @ The University of Melbourne
 
20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)
20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)
20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)
James Jungkue Lee
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
Anthony Melvin Crasto Ph.D
 
Hatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigationsHatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigations
AnumulaSurendra
 

Viewers also liked (20)

Hatch Waxman Act
Hatch Waxman ActHatch Waxman Act
Hatch Waxman Act
 
Evergreening of patents in pharma field (Rahul Pokale)
Evergreening of patents in pharma field (Rahul Pokale)Evergreening of patents in pharma field (Rahul Pokale)
Evergreening of patents in pharma field (Rahul Pokale)
 
Biopolymers_highlights2014-2015
Biopolymers_highlights2014-2015Biopolymers_highlights2014-2015
Biopolymers_highlights2014-2015
 
Knowledge management
Knowledge managementKnowledge management
Knowledge management
 
Produce the Perfect Product Launch
Produce the Perfect Product LaunchProduce the Perfect Product Launch
Produce the Perfect Product Launch
 
Stanford DrupalCamp 2014 - A Perfect Launch, Every Time
Stanford DrupalCamp 2014 - A Perfect Launch, Every TimeStanford DrupalCamp 2014 - A Perfect Launch, Every Time
Stanford DrupalCamp 2014 - A Perfect Launch, Every Time
 
Kesselheim slides
Kesselheim slidesKesselheim slides
Kesselheim slides
 
Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...
Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...
Biosimilars, Orphans, Advanced Therapy Medicines: Current regulatory issues (...
 
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
 
What you want to know about generic drugs
What you want to know about generic drugsWhat you want to know about generic drugs
What you want to know about generic drugs
 
Biosimilars 10-21-2010
Biosimilars 10-21-2010Biosimilars 10-21-2010
Biosimilars 10-21-2010
 
Timeline of Biosimilars Pathways
Timeline of Biosimilars PathwaysTimeline of Biosimilars Pathways
Timeline of Biosimilars Pathways
 
Biosimilars Law in Flux
Biosimilars Law in FluxBiosimilars Law in Flux
Biosimilars Law in Flux
 
U.S. Biosimilars - Red Flags for Patent Attorneys
U.S. Biosimilars - Red Flags for Patent AttorneysU.S. Biosimilars - Red Flags for Patent Attorneys
U.S. Biosimilars - Red Flags for Patent Attorneys
 
Monoclonal Antibodies Dawn Of A New Era
Monoclonal Antibodies Dawn Of A New EraMonoclonal Antibodies Dawn Of A New Era
Monoclonal Antibodies Dawn Of A New Era
 
A history of pharma v1
A history of pharma v1A history of pharma v1
A history of pharma v1
 
New sources of big data for precision medicine: are we ready?
New sources of big data for precision medicine: are we ready?New sources of big data for precision medicine: are we ready?
New sources of big data for precision medicine: are we ready?
 
20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)
20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)
20121130 신약연구개발 동향 (한국형 신약 r&d open innovation 전략 심포지엄)
 
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crastoABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
ABBREVIATED NEW DRUG APPLICATION (ANDA) by Anthony crasto
 
Hatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigationsHatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigations
 

Similar to When do drug patents expire and when can generic drugs launch?

Generic drug approval in the United States - ANDA regulations
Generic drug approval in the United States - ANDA regulationsGeneric drug approval in the United States - ANDA regulations
Generic drug approval in the United States - ANDA regulations
Steve Zweig
 
Hatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika DeyHatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika Dey
Kushal Saha
 
A Pathway for Pharmaceutical Patents
A Pathway for Pharmaceutical PatentsA Pathway for Pharmaceutical Patents
A Pathway for Pharmaceutical Patents
Aurora Consulting
 
guide.pdf
guide.pdfguide.pdf
Market Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch ActMarket Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch Act
Michael Swit
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
Sujith Thokala
 
IP business transaction slides
IP business transaction slidesIP business transaction slides
IP business transaction slides
Marta Delsignore
 
Intellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug DevelopmentIntellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug Development
MaryBreenSmith
 
ABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUES
ABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUESABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUES
ABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUES
Michael Swit
 
Drug development process and regulatory submissions
Drug development process and regulatory submissionsDrug development process and regulatory submissions
Drug development process and regulatory submissions
Suyog
 
Presentation on ANDA litigation
Presentation on ANDA litigationPresentation on ANDA litigation
Presentation on ANDA litigation
Vikram Jeet Singh
 
Hatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptxHatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptx
Sumeet Dhakane
 
RegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleRegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycle
HarunMohamed7
 
Overview of US FDA: Drugs
Overview of US FDA: DrugsOverview of US FDA: Drugs
Overview of US FDA: Drugs
Gaurav Andhansare
 
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
Michael Swit
 
LIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVE
LIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVELIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVE
LIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVE
Michael Swit
 
ANDA.pptx
ANDA.pptxANDA.pptx
ANDA.pptx
HarshikhaMathur
 

Similar to When do drug patents expire and when can generic drugs launch? (20)

Generic drug approval in the United States - ANDA regulations
Generic drug approval in the United States - ANDA regulationsGeneric drug approval in the United States - ANDA regulations
Generic drug approval in the United States - ANDA regulations
 
Hatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika DeyHatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika Dey
 
A Pathway for Pharmaceutical Patents
A Pathway for Pharmaceutical PatentsA Pathway for Pharmaceutical Patents
A Pathway for Pharmaceutical Patents
 
guide.pdf
guide.pdfguide.pdf
guide.pdf
 
Hatch waxman act
Hatch waxman actHatch waxman act
Hatch waxman act
 
Market Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch ActMarket Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch Act
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
IP business transaction slides
IP business transaction slidesIP business transaction slides
IP business transaction slides
 
Intellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug DevelopmentIntellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug Development
 
ABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUES
ABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUESABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUES
ABBREVIATED NEW DRUG APPLICATIONS & PATENT/EXCLUSIVITY ISSUES
 
Anda ppt
Anda pptAnda ppt
Anda ppt
 
Drug development process and regulatory submissions
Drug development process and regulatory submissionsDrug development process and regulatory submissions
Drug development process and regulatory submissions
 
Presentation on ANDA litigation
Presentation on ANDA litigationPresentation on ANDA litigation
Presentation on ANDA litigation
 
Hatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptxHatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptx
 
RegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleRegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycle
 
Overview of US FDA: Drugs
Overview of US FDA: DrugsOverview of US FDA: Drugs
Overview of US FDA: Drugs
 
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key IssuesANDAs, OTCs, Orphans and Cosmetics – Key Issues
ANDAs, OTCs, Orphans and Cosmetics – Key Issues
 
LIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVE
LIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVELIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVE
LIFECYCLE MANAGEMENT STRATEGIES: THE GENERIC PERSPECTIVE
 
ANDA.pptx
ANDA.pptxANDA.pptx
ANDA.pptx
 
Binder1.pdf
Binder1.pdfBinder1.pdf
Binder1.pdf
 

More from thinkBiotech

Defeating COVID-19
Defeating COVID-19Defeating COVID-19
Defeating COVID-19
thinkBiotech
 
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
thinkBiotech
 
Finding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunitiesFinding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunities
thinkBiotech
 
Building Biotechnology in India
Building Biotechnology in IndiaBuilding Biotechnology in India
Building Biotechnology in IndiathinkBiotech
 
Pharmaceutical globalization: Where are drugs invented?
Pharmaceutical globalization: Where are drugs invented?Pharmaceutical globalization: Where are drugs invented?
Pharmaceutical globalization: Where are drugs invented?
thinkBiotech
 
Using patent information to track globalization
Using patent information to track globalizationUsing patent information to track globalization
Using patent information to track globalization
thinkBiotech
 
Educating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and FoundersEducating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and Founders
thinkBiotech
 
Innovating Across Borders
Innovating Across BordersInnovating Across Borders
Innovating Across Borders
thinkBiotech
 
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
thinkBiotech
 
Functional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology IndustryFunctional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology Industry
thinkBiotech
 

More from thinkBiotech (10)

Defeating COVID-19
Defeating COVID-19Defeating COVID-19
Defeating COVID-19
 
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
 
Finding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunitiesFinding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunities
 
Building Biotechnology in India
Building Biotechnology in IndiaBuilding Biotechnology in India
Building Biotechnology in India
 
Pharmaceutical globalization: Where are drugs invented?
Pharmaceutical globalization: Where are drugs invented?Pharmaceutical globalization: Where are drugs invented?
Pharmaceutical globalization: Where are drugs invented?
 
Using patent information to track globalization
Using patent information to track globalizationUsing patent information to track globalization
Using patent information to track globalization
 
Educating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and FoundersEducating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and Founders
 
Innovating Across Borders
Innovating Across BordersInnovating Across Borders
Innovating Across Borders
 
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
 
Functional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology IndustryFunctional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology Industry
 

Recently uploaded

Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 

Recently uploaded (20)

Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 

When do drug patents expire and when can generic drugs launch?